Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

Similar articles for PubMed (Select 15956187)

1.

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.

Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T.

Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9406-11. Epub 2005 Jun 14.

2.

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.

Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD.

Nat Med. 2005 Aug;11(8):861-6. Epub 2005 Jul 10.

PMID:
16007095
3.

Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.

Borsting E, Cheng VP, Glass CK, Vallon V, Cunard R.

Am J Physiol Renal Physiol. 2012 Mar 1;302(5):F540-51. doi: 10.1152/ajprenal.00306.2011. Epub 2011 Dec 14.

4.

Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters.

Zhou L, Liu G, Jia Z, Yang KT, Sun Y, Kakizoe Y, Liu M, Zhou S, Chen R, Yang B, Yang T.

Am J Physiol Renal Physiol. 2013 Nov 15;305(10):F1491-7. doi: 10.1152/ajprenal.00004.2013. Epub 2013 Sep 4.

5.

Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.

Schinner S, Krätzner R, Baun D, Dickel C, Blume R, Oetjen E.

Br J Pharmacol. 2009 Jul;157(5):736-45. doi: 10.1111/j.1476-5381.2009.00208.x. Epub 2009 Mar 26.

6.

Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.

Pavlov TS, Levchenko V, Karpushev AV, Vandewalle A, Staruschenko A.

Mol Pharmacol. 2009 Dec;76(6):1333-40. doi: 10.1124/mol.109.056911. Epub 2009 Sep 14.

7.

Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats.

Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA.

J Pharmacol Exp Ther. 2004 Feb;308(2):426-33. Epub 2003 Oct 30.

8.

A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.

Eur J Pharmacol. 2008 Apr 14;584(1):192-201. doi: 10.1016/j.ejphar.2007.12.036. Epub 2008 Feb 14.

PMID:
18346728
9.

T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.

Li Y, Wang Z, Furukawa N, Escaron P, Weiszmann J, Lee G, Lindstrom M, Liu J, Liu X, Xu H, Plotnikova O, Prasad V, Walker N, Learned RM, Chen JL.

J Biol Chem. 2008 Apr 4;283(14):9168-76. doi: 10.1074/jbc.M800104200. Epub 2008 Feb 7.

10.

Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity.

Vallon V, Hummler E, Rieg T, Pochynyuk O, Bugaj V, Schroth J, Dechenes G, Rossier B, Cunard R, Stockand J.

J Am Soc Nephrol. 2009 Apr;20(4):721-9. doi: 10.1681/ASN.2008040415. Epub 2009 Jan 21.

11.

Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake.

Panchapakesan U, Pollock C, Saad S.

Nephrology (Carlton). 2009 Apr;14(3):298-301. Review.

PMID:
19444964
12.

PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.

Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.

Arch Pharm Res. 2009 May;32(5):721-7. doi: 10.1007/s12272-009-1511-8. Epub 2009 May 27.

PMID:
19471887
13.

Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.

Lu M, Sarruf DA, Talukdar S, Sharma S, Li P, Bandyopadhyay G, Nalbandian S, Fan W, Gayen JR, Mahata SK, Webster NJ, Schwartz MW, Olefsky JM.

Nat Med. 2011 May;17(5):618-22. doi: 10.1038/nm.2332. Epub 2011 May 1.

14.
15.

Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.

Higashi Y, Holder K, Delafontaine P.

J Biol Chem. 2010 Nov 19;285(47):36361-8. doi: 10.1074/jbc.M110.137661. Epub 2010 Sep 15.

17.

Thiazolidinediones alter growth and epithelial cell integrity, independent of PPAR-γ and MAPK activation, in mouse M1 cortical collecting duct cells.

Nasrallah R, Clark J, Corinaldi J, Paris G, Miura P, Jasmin BJ, Hébert RL.

Am J Physiol Renal Physiol. 2010 May;298(5):F1105-12. doi: 10.1152/ajprenal.00735.2009. Epub 2010 Feb 17.

18.

Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.

Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM.

Eur J Pharmacol. 2008 Oct 31;596(1-3):173-9. doi: 10.1016/j.ejphar.2008.08.004. Epub 2008 Aug 16.

PMID:
18761337
19.
20.

Activation of peroxisome proliferator-activated receptor-γ downregulates soluble epoxide hydrolase in cardiomyocytes.

Pang W, Li N, Ai D, Niu XL, Guan YF, Zhu Y.

Clin Exp Pharmacol Physiol. 2011 Jun;38(6):358-64. doi: 10.1111/j.1440-1681.2011.05492.x.

PMID:
21291492
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk